A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Exclusion Criteria

• •1. Active Central Nervous System (CNS) involvement by malignancy.
• •2. Isolated extra-medullary disease relapse.
• •3. Patients with Burkitt's lymphoma/leukemia, mixed phenotypic acute leukemia and Chronic Myelogenous Leukemia in Blast Crisis
• •4. History of concomitant genetic syndrome
• •5. Patients with acute graft-versus-host disease (GVHD) or moderate-to-severe chronic GVHD within 4 weeks before screening.
• •6. Active systemic autoimmune disease
• •7. Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive).
• •8. Patients with active infections at screening.
• •9. Patients who received specified chemotherapy before CNCT19 infusion
• •10. Radiotherapy before CNCT19 infusion:
• •Non-CNS site of radiation completed \< 4 weeks prior to CNCT19 Infusion; CNS directed radiation completed \< 8 weeks prior to CNCT19 infusion.
• •11. Donor lymphocyte infusion (DLI) must be stopped \> 6 week prior to CNCT19 infusion.
• •12. Has had treatment with any prior CAR-T therapy.
• •13. Life expectancy \< 3 months.